Four new HLA alleles were identified using the monoallelic Sanger sequencing method: . A distinctive feature of the method is to implement the initial allele-specific PCR products for subsequent separate amplification of the target gene alleles. This, in turn, allows for sequencing of each allele separately and avoiding ambiguous HLA typing results observed when performing locus-specific sequencing.
Introduction
The Major Histocompatibility Complex (MHC) is among the most polymorphic genetic systems in humans. Over last decade, extensive research in HLA (Human Leukocyte Antigens) has revealed hundreds of new HLA allelles by means of intensive application of immunogenetic sequencing methods, including monoallelic Sanger-sequencing method, or, more recently, next-generation sequencing (Fig. 1) .
In June 2017, the database of the World Health Organization (WHO) Nomenclature Committee for Factors of the HLA System (IPD-IMGT/HLA Database) contained information on the nucleotide sequences of 17331 different HLA alleles, of which 12631 were HLA class I, and 4700 were found for the HLA class II alleles [1] [2] [3] . 13500  13000  12500  12000  11500  11000  10500  10000  9500  9000  8500  8000  7500  7000  6500  6000  5500  5000  4500  4000  3500  3000  2500  2000  1500  1000  500  0  1987  1989  1990 The aim of this study was to evaluate the advantages of using monoallelic Sanger sequencing approach as a necessary step of identifying new HLA alleles.
Materials and methods
The test samples were obtained from potential donors of Bone Marrow Donor Registry of the I. P. Pavlov State Medical University in St. Petersburg and from a patient with acute myeloblastic leukemia who underwent HLA testing for subsequent allogeneic hematopoietic stem cell transplantation. Genomic DNA was isolated from peripheral blood leukocytes by a proteinase method using columns with a silica gel membrane and a kit PROTRANS DNA BOX reagents (Protrans, Germany). The target DNA concentration was 30 ng/ μL. Quantity and quality estimation of the isolated DNA was performed with Thermo Scientific NanoDrop 2000 Spectrophotometer. The quality of isolated DNA was estimated as an optical density ratio at of 260/280 nm wavelength, with reference range of 1.6-1.8.
Immunogenetic studies were done using the method of monoallelic Sanger sequencing. Initial and control studies were performed for each sample. To perform a control typing, the DNA was isolated from the newly collected biomaterial. The Protrans reagent kits (Germany) were used as follows: PRO-TRANS S4 HLA-A * Cyclerstrips, PROTRANS S4 HLA-B * Cyclerstrips, PROTRANS S4 HLA-C * Cyclerstrips, PRO-TRANS S4 HLA-DRB1 * Cyclerstrip, PROTRANS S3 HLA-DQB1 * Cyclerstrips. To identify HLA class I alleles (HLA-A, HLA-B, HLA-C), we sequenced exons 2-3; for class II HLA alleles (HLA-DRB1, HLA-DQB1) we sequenced exon 2.
Capillary electrophoresis was performed using Applied Biosystems 3500xl genetic analyzer (USA). To specify nucleotide sequences of the target alleles, the rough laboratory data were evaluated with Sequens Pilot software, version 4.1.2 (JSI Medical Systems, Germany).
Results
The method of monoallelic Sanger sequencing is routinely applied at the tissue typing laboratory of St. Petersburg State Medical University I. P. Pavlov since 2010. A special feature of this method is carrying out allele-specific PCR at the initial stage, which usually leads to separate amplification of the analyzed gene alleles. After separate amplification, each allele may be subject to isolated sequencing.
The allele-specific sequencing allows of avoiding the socalled cis-trans ambiguities which occur when interpreting HLA typing results. About 90% of people are known to be heterozygous for each HLA gene, thus causing cis-trans ambiguities precluding the exact HLA genotyping after locus-specific sequencing [4] .
Using an allele-specific sequencing approach, the novel al According to the version 3.26.0 of the IPD-IMGT/HLA database, the nucleotide sequence of the exon 2 of the new HLA-DRB1*01 allele differs from the nearest homologue HLA-DRB1*01:01:01 in position 279 (thymine is determined instead of guanine), for details see Fig. 5 .
